Truist Securities Maintains Buy on CG Oncology, Raises Price Target to $85

CG Oncology, Inc.

CG Oncology, Inc.

CGON

0.00

Truist Securities analyst Gregory Renza maintains CG Oncology (NASDAQ: CGON) with a Buy and raises the price target from $82 to $85.